Early access
Sign in
Enrolling by invitationPhase 2

Continued treatment with IMVT-1402 for adults with Graves' disease

Tests IMVT-1402 over a longer time in adults with Graves' disease.

Key facts

Who runs it
Immunovant Sciences GmbH
Where
Asheville, Atlanta, Aurora, Austin, Baltimore, Bellaire, Boston, Bowling Green, Canton, Chapel Hill, Chattanooga, Clearwater, Columbus, Concord, Dallas, Doral, El Paso, Englewood, Farmington Hills, Flint, Florence, Fort Worth, Gulfport, Hialeah, Hickory, Houston, Huntington Beach, Indianapolis, Irving, Jacksonville, Jefferson City, Kansas City, Las Vegas, Los Angeles, Louisville, Macon, McKinney, Memphis, Mesquite, Metairie, Miami, Monroe, Morehead City, Nashville, New Hyde Park, New Orleans, New York, Newark, Norfolk, Ocoee, Oklahoma City, Omaha, Orange, Orlando, Philadelphia, Phoenix, Port Charlotte, Portland, Pottstown, Raleigh, Reno, Rochester, Round Rock, Salt Lake City, San Antonio, San Francisco, Sandy City, Santa Clarita, Stockbridge, Summerville, Topeka, Torrance, Tucson, Washington D.C., West Palm Beach, Williamsville, and Wilmington, United StatesSee the 89 sitesAlso in 10 other countries, 42 sites
Trial code
Registry title
A Long-Term Extension Study of IMVT-1402 in Adult Participants With Graves' Disease (GD)
Status
Enrolling by invitation
Phase
Phase 2
People taking part
372 people, planned
Started
26 Jan 2026
Expected to end
Mar 2030
Type of study
Interventional, 3 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • IMVT-1402
Record updated
29 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with Graves' disease who completed one of two earlier IMVT-1402 studies. People are placed in 1 of 3 groups based on their disease status at the end of that study.

Age
18 Years and older
Sex
All sexes can join
Disease stage
Graves' disease, an overactive thyroid caused by the immune system
Earlier treatment
Must have completed Study IMVT-1402-2502 (NCT06727604) or Study IMVT-1402-2503 (NCT07018323).

Main reasons for not taking part

  • Permanently stopped the study drug during the treatment period of the earlier study
  • Met the study stopping rules at any point in the earlier study
  • Other, more specific criteria are set in the protocol

The registry criteria, word for word

Show all 3 criteriaShow less

Who can take part

  • Participants who completed Study IMVT-1402-2502 or Study IMVT-1402-2503
  • Other, more specific inclusion criteria are defined in the protocol

Who cannot take part

  • Have permanently discontinued IMP during the treatment period in the feeder study or have met study stopping criteria at any point up until the end of participation in the feeder study

Where in United States

Also in 10 other countries, 42 sites

  • Asheville, North CarolinaHospital not named in the registryEnrolling by invitation
  • Atlanta, GeorgiaHospital not named in the registryEnrolling by invitation
  • Aurora, ColoradoHospital not named in the registryEnrolling by invitation
  • Austin, TexasHospital not named in the registryEnrolling by invitation
  • Baltimore, MarylandHospital not named in the registryEnrolling by invitation
  • Bellaire, TexasHospital not named in the registryEnrolling by invitation
  • Boston, MassachusettsHospital not named in the registryEnrolling by invitation
  • Bowling Green, KentuckyHospital not named in the registryEnrolling by invitation
  • Canton, OhioHospital not named in the registryEnrolling by invitation
  • Chapel Hill, North CarolinaHospital not named in the registryEnrolling by invitation
  • Chattanooga, TennesseeHospital not named in the registryEnrolling by invitation
  • Clearwater, FloridaHospital not named in the registryEnrolling by invitation
  • Columbus, GeorgiaHospital not named in the registryEnrolling by invitation
  • Concord, CaliforniaHospital not named in the registryEnrolling by invitation
  • Dallas, TexasHospital not named in the registryEnrolling by invitation
  • Dallas, TexasHospital not named in the registryEnrolling by invitation
  • Dallas, TexasHospital not named in the registryEnrolling by invitation
  • Doral, FloridaHospital not named in the registryEnrolling by invitation
  • El Paso, TexasHospital not named in the registryEnrolling by invitation
  • Englewood, ColoradoHospital not named in the registryEnrolling by invitation
  • Farmington Hills, MichiganHospital not named in the registryEnrolling by invitation
  • Flint, MichiganHospital not named in the registryEnrolling by invitation
  • Florence, KentuckyHospital not named in the registryEnrolling by invitation
  • Fort Worth, TexasHospital not named in the registryEnrolling by invitation
  • Gulfport, MississippiHospital not named in the registryEnrolling by invitation
  • Hialeah, FloridaHospital not named in the registryEnrolling by invitation
  • Hickory, North CarolinaHospital not named in the registryEnrolling by invitation
  • Houston, TexasHospital not named in the registryEnrolling by invitation
  • Huntington Beach, CaliforniaHospital not named in the registryEnrolling by invitation
  • Indianapolis, IndianaHospital not named in the registryEnrolling by invitation
  • Irving, TexasHospital not named in the registryEnrolling by invitation
  • Jacksonville, FloridaHospital not named in the registryEnrolling by invitation
  • Jacksonville, FloridaHospital not named in the registryEnrolling by invitation
  • Jefferson City, MissouriHospital not named in the registryEnrolling by invitation
  • Kansas City, MissouriHospital not named in the registryEnrolling by invitation
  • Kansas City, KansasHospital not named in the registryEnrolling by invitation
  • Las Vegas, NevadaHospital not named in the registryEnrolling by invitation
  • Los Angeles, CaliforniaHospital not named in the registryEnrolling by invitation
  • Louisville, KentuckyHospital not named in the registryEnrolling by invitation
  • Macon, GeorgiaHospital not named in the registryEnrolling by invitation
  • McKinney, TexasHospital not named in the registryEnrolling by invitation
  • Memphis, TennesseeHospital not named in the registryEnrolling by invitation
  • Mesquite, TexasHospital not named in the registryEnrolling by invitation
  • Metairie, LouisianaHospital not named in the registryEnrolling by invitation
  • Miami, FloridaHospital not named in the registryEnrolling by invitation
  • Miami, FloridaHospital not named in the registryEnrolling by invitation
  • Miami, FloridaHospital not named in the registryEnrolling by invitation
  • Monroe, New YorkHospital not named in the registryEnrolling by invitation
  • Morehead City, North CarolinaHospital not named in the registryEnrolling by invitation
  • Nashville, TennesseeHospital not named in the registryEnrolling by invitation
  • Nashville, TennesseeHospital not named in the registryEnrolling by invitation
  • New Hyde Park, New YorkHospital not named in the registryEnrolling by invitation
  • New Orleans, LouisianaHospital not named in the registryEnrolling by invitation
  • New YorkHospital not named in the registryEnrolling by invitation
  • New YorkHospital not named in the registryEnrolling by invitation
  • Newark, DelawareHospital not named in the registryEnrolling by invitation
  • Norfolk, VirginiaHospital not named in the registryEnrolling by invitation
  • Ocoee, FloridaHospital not named in the registryEnrolling by invitation
  • Oklahoma City, OklahomaHospital not named in the registryEnrolling by invitation
  • Omaha, NebraskaHospital not named in the registryEnrolling by invitation
  • Orange, CaliforniaHospital not named in the registryEnrolling by invitation
  • Orlando, FloridaHospital not named in the registryEnrolling by invitation
  • Philadelphia, PennsylvaniaHospital not named in the registryEnrolling by invitation
  • Phoenix, ArizonaHospital not named in the registryEnrolling by invitation
  • Phoenix, ArizonaHospital not named in the registryEnrolling by invitation
  • Port Charlotte, FloridaHospital not named in the registryEnrolling by invitation
  • Portland, OregonHospital not named in the registryEnrolling by invitation
  • Pottstown, PennsylvaniaHospital not named in the registryEnrolling by invitation
  • Raleigh, North CarolinaHospital not named in the registryEnrolling by invitation
  • Reno, NevadaHospital not named in the registryEnrolling by invitation
  • Rochester, MinnesotaHospital not named in the registryEnrolling by invitation
  • Round Rock, TexasHospital not named in the registryEnrolling by invitation
  • Salt Lake City, UtahHospital not named in the registryEnrolling by invitation
  • San Antonio, TexasHospital not named in the registryEnrolling by invitation
  • San Antonio, TexasHospital not named in the registryEnrolling by invitation
  • San Antonio, TexasHospital not named in the registryEnrolling by invitation
  • San Antonio, TexasHospital not named in the registryEnrolling by invitation
  • San Francisco, CaliforniaHospital not named in the registryEnrolling by invitation
  • Sandy City, UtahHospital not named in the registryEnrolling by invitation
  • Santa Clarita, CaliforniaHospital not named in the registryEnrolling by invitation
  • Stockbridge, GeorgiaHospital not named in the registryEnrolling by invitation
  • Summerville, South CarolinaHospital not named in the registryEnrolling by invitation
  • Topeka, KansasHospital not named in the registryEnrolling by invitation
  • Torrance, CaliforniaHospital not named in the registryEnrolling by invitation
  • Tucson, ArizonaHospital not named in the registryEnrolling by invitation
  • Washington D.C., District of ColumbiaHospital not named in the registryEnrolling by invitation
  • West Palm Beach, FloridaHospital not named in the registryEnrolling by invitation
  • Williamsville, New YorkHospital not named in the registryEnrolling by invitation
  • Wilmington, North CarolinaHospital not named in the registryEnrolling by invitation

About the trial

What the trial wants to find out

This is a long-term extension study that will rollover participants completing feeder studies IMVT-1402-2502 (NCT06727604) or IMVT-1402-2503 (NCT07018323) to evaluate the efficacy and safety of IMVT-1402 in adult participants with GD. Eligible participants will be assigned to 1 of 3 study groups (Groups A, B and C) based on their GD status at the completion of their respective feeder study.

The 3 groups in the trial

  • Group ATreatment being tested

    Treatment: IMVT-1402

  • Group BNo study treatment, for comparison
  • Group CNo study treatment, for comparison

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Long-Term Extension Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Patients With Graves' Disease
Plain-language title
Continued treatment with IMVT-1402 for adults with Graves' diseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
29 September 2026